PharmaMar Seeks EU Approval for Aplidin to Treat Multiple Myeloma
PharmaMar has submitted a Marketing Authorization Application (MAA) to the …
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Clinical Trial Aims to Unravel Genetic Markers of MRD in Multiple Myeloma Patients
The Multiple Myeloma Research Foundation (MMRF) and the…
Excess Body Fat Increases Risk for 8 More Cancer Types, Special Report Says
The association between excess body fat and increased risk…
Minimal Residual Disease in Myeloma Suggested as Clinical Trial Endpoint, but Experts Disagree
Minimal residual disease, a measurement that shows a low…
Janssen Seeks to Expand Darzalex Use for Multiple Myeloma Patients
Janssen Biotech has submitted a supplemental Biologics License…
In Heavily Treated Myeloma Patients, Selinexor-Dexamethasone Combo Shows Positive Results
Patients with heavily treated multiple myeloma have promising response…
